Literature DB >> 21113572

[MRI for therapy control in patients with aortic isthmus stenosis].

B J Wintersperger1, D Theisen, M F Reiser.   

Abstract

Aortic isthmus stenosis is the most common congenital aortic anomaly and is often a problem for therapy surveillance. In addition to possible comorbidities (e.g. bicuspid aortic valve) it is accompanied by various middle and long-term complications depending on the primary choice of the therapeutic procedure. Magnetic resonance imaging (MRI) plays an important role for the mostly young patients in the control of the aortic isthmus stenosis and therapy because it is non-invasive and there is no X-ray exposure. Radiologists should be well-informed on the principles of the therapeutic procedure in order to be competent in the interpretation of MRI findings. Due to the continuous development of MRI technology, techniques for functional evaluation (e.g. dynamic MRA, 4D PC flow measurement) are increasingly becoming available in addition to high-resolution MR angiography (MRA), which could predict the risk of possible complications, such as aneurysms. However, in this aspect further studies are necessary. Interventional therapy with stents and stent grafts is often employed for the therapy of possible complications following an operation (aneurysms, restenosis) but because of massive metal artefacts the use of MRI is often sometimes severely limited.

Entities:  

Mesh:

Year:  2011        PMID: 21113572     DOI: 10.1007/s00117-010-1997-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  47 in total

1.  Comprehensive cardiac magnetic resonance imaging at 3.0 Tesla: feasibility and implications for clinical applications.

Authors:  Matthias Gutberlet; Ralph Noeske; Kerstin Schwinge; Patrick Freyhardt; Roland Felix; Thoralf Niendorf
Journal:  Invest Radiol       Date:  2006-02       Impact factor: 6.016

2.  Myocardial perfusion imaging with Gadobutrol: a comparison between 3 and 1.5 Tesla with an identical sequence design.

Authors:  Daniel Theisen; Bernd J Wintersperger; Armin Huber; Olaf Dietrich; Maximilian F Reiser; Stefan O Schönberg
Journal:  Invest Radiol       Date:  2007-07       Impact factor: 6.016

Review 3.  Body MR imaging at 3.0 T: understanding the opportunities and challenges.

Authors:  Mara M Barth; Martin P Smith; Ivan Pedrosa; Robert E Lenkinski; Neil M Rofsky
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

4.  Motion artifacts in fast spin-echo imaging.

Authors:  B Madore; R M Henkelman
Journal:  J Magn Reson Imaging       Date:  1994 Jul-Aug       Impact factor: 4.813

5.  [3 tesla magnetic resonance imaging in children and adults with congenital heart disease].

Authors:  I Voges; M Jerosch-Herold; M Helle; C Hart; H-H Kramer; C Rickers
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

6.  Coarctation of the aorta: collateral flow assessment with phase-contrast MR angiography.

Authors:  P R Julsrud; J F Breen; J P Felmlee; C A Warnes; H M Connolly; H V Schaff
Journal:  AJR Am J Roentgenol       Date:  1997-12       Impact factor: 3.959

Review 7.  Velocity-encoded cine MR imaging in aortic coarctation: functional assessment of hemodynamic events.

Authors:  Jeffrey J Hom; Karen Ordovas; Gautham P Reddy
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

8.  Trends in congenital heart disease in Dallas County births. 1971-1984.

Authors:  D E Fixler; P Pastor; M Chamberlin; E Sigman; C W Eifler
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

9.  Transverse arch hypoplasia predisposes to aneurysm formation at the repair site after patch angioplasty for coarctation of the aorta.

Authors:  J Bogaert; M Gewillig; F Rademakers; H Bosmans; J Verschakelen; W Daenen; A L Baert
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

Review 10.  [Congenital abnormalities of the aorta in children and adolescents].

Authors:  J G Eichhorn; S Ley
Journal:  Radiologe       Date:  2007-11       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.